PAR PHARM INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?
PAR PHARM INC has twelve approved drugs.
There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.
There are nine patent family members on PAR PHARM INC drugs in eight countries and twenty-three supplementary protection certificates in thirteen countries.
Drugs and US Patents for PAR PHARM INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Par Pharm Inc | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | TABLET;ORAL | 207170-001 | Jan 26, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Par Pharm Inc | NUBAIN | nalbuphine hydrochloride | INJECTABLE;INJECTION | 018024-002 | May 27, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Par Pharm Inc | DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 206159-005 | May 31, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Par Pharm Inc | ETHACRYNIC ACID | ethacrynic acid | TABLET;ORAL | 208501-001 | Jul 21, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PAR PHARM INC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 1948613 | ⤷ Sign Up |
Canada | 2605413 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2006115626 | ⤷ Sign Up |
Japan | 5378788 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PAR PHARM INC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2330892 | 359 5034-2016 | Slovakia | ⤷ Sign Up | PRODUCT NAME: GLYCEROLFENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 20151201 |
2330892 | 2016/064 | Ireland | ⤷ Sign Up | PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REGISTRATION NO/DATE: EU/1/15/1062 20151201 |
0785926 | SPC/GB08/047 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AMBRISENTAN; REGISTERED: UK EU/1/08/451/001 20080421; UK EU/1/08/451/002 20080421; UK EU/1/08/451/003 20080421; UK EU/1/08/451/004 20080421 |
2330892 | 2016C/074 | Belgium | ⤷ Sign Up | PRODUCT NAME: GLYCEROLFENYLBUTYRAAT; AUTHORISATION NUMBER AND DATE: EU/1/15/1062 20151201 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.